Last reviewed · How we verify
L19IL2 at RD - Ph II — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
L19IL2 at RD - Ph II (L19IL2 at RD - Ph II) — Philogen S.p.A..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| L19IL2 at RD - Ph II TARGET | L19IL2 at RD - Ph II | Philogen S.p.A. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- L19IL2 at RD - Ph II CI watch — RSS
- L19IL2 at RD - Ph II CI watch — Atom
- L19IL2 at RD - Ph II CI watch — JSON
- L19IL2 at RD - Ph II alone — RSS
Cite this brief
Drug Landscape (2026). L19IL2 at RD - Ph II — Competitive Intelligence Brief. https://druglandscape.com/ci/l19il2-at-rd-ph-ii. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab